Park Avenue Securities LLC Acquires 8,615 Shares of Sanofi (NASDAQ:SNY)

Park Avenue Securities LLC increased its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 14.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,982 shares of the company's stock after buying an additional 8,615 shares during the period. Park Avenue Securities LLC's holdings in Sanofi were worth $3,327,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Northwest Investment Counselors LLC bought a new stake in shares of Sanofi in the 3rd quarter valued at about $29,000. Concord Wealth Partners increased its stake in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after purchasing an additional 363 shares in the last quarter. Fortitude Family Office LLC increased its stake in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock valued at $43,000 after purchasing an additional 659 shares in the last quarter. Sunbelt Securities Inc. raised its holdings in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock worth $43,000 after purchasing an additional 313 shares during the period. Finally, Versant Capital Management Inc bought a new position in shares of Sanofi during the fourth quarter worth $54,000. 14.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $57.50.

Sanofi Stock Performance

SNY stock remained flat at $50.74 during mid-day trading on Friday. 2,426,236 shares of the company's stock traded hands, compared to its average volume of 2,532,340. The company has a market cap of $128.77 billion, a price-to-earnings ratio of 25.89, a P/E/G ratio of 1.17 and a beta of 0.57. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The business has a fifty day simple moving average of $48.47 and a 200 day simple moving average of $52.08.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company's revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.55 EPS. On average, equities research analysts predict that Sanofi will post 3.94 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.